Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$VTNR dip opportunities or news already baked in? Knew the news was coming, I still think new HOD is on the way. We’ll see!
$VTNR - Interesting...seeing reports and screen shots on stocktwits showing that Shell posted an update that the sale of their refinery to Vertex is complete. No official news yet, in the terms of an 8K, but the link is apparently down now from the Shell site...
Interesting price action...was pretty sure we'd see a pop to $14-$15ish on the news...but...I guess we'll see.
$VTNR with the early morning dip and rip!
$SMFL - I'm ready for a run. I like the weekly chart...could make one hell of a cup if it busts out today or next week and gets back to the IPO price!
$MITQ $1.46...fairly low volume though. If this one can just catch that volume surge, it could push nicely. I know some would refer to this as a "micro-crap", but this is one to me where the pps simply doesn't make sense when considering simple things like revenue guidance and cash on hand.
$VTNR booming AH's!!! Could be a fun PM if they drop news on closing the purchase of the refinery in Mobile, AL.
$SMFL $1.11 HOD...this one seems like it's coiling and just waiting to really break out. My thoughts are that it goes higher than we saw in the PM last week in the $1.70's...IPO was $10...has been no where close to that price since.
$VTNR just topped $10!
$VTNR getting some pre-market love. News should be coming today, or in the coming days, of closure of the refinery that they are purchasing from Shell. This refinery will be converted/modified to enable them to produce their biodiesel, with those efforts to start in 2023.
Ran as high as $15 and change almost a year ago when this was first announced...their future rev's will be through the roof in comparison to now...we'll see what the market says though. As far as I know, the PT's issued last May/June haven't changed, with around $25.
About 25% of the float is short, per Yahoo...so could put on a nice squeeze. I'd be happy with the squeeze to $20-$25, but would obviously take more if the market is going to give it!!!
$NAOV - I'm tempted to day trade this again today...especially if the pps drops sub $1 to that .92-.95 range. The volume is a far cry from yesterday, but basically 2.5x the float traded yesterday, and most at prices above where it currently trades at $1.07.
Question is...move on and wait for the next...or try to revisit the hand that feeds?
$SNTG - Look at that volume already! Wowzer!
$MITO news article...
Sorry, Orions...didn't realize that this apparently only came through the Fidelity newswire, as I didn't see this on Yahoo either...I don't have the link, but here is a copy and paste of what came through. I was wondering why the news really didn't drive any price action...maybe tomorrow after it gets out to more sources?
Stealth BioTherapeutics Announces New SBT-272 Data and Trial Initiation
PR NEWSWIRE 3:30 PM ET 3/30/2022
Symbol Last Price Change
MITO 0.7down +0.0084 (+1.2146%)
QUOTES AS OF 04:00:01 PM ET 03/30/2022
BOSTON , March 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp(MITO) , a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-272 preclinical data at the Mitochondrial Biochemistry in Health and Disease Symposium in Breckenridge, CO and dosing of the first subject in its Phase 1 clinical trial of SBT-272.
Stealth BioTherapeutics Logo (PRNewsFoto/Stealth BioTherapeutics) (PRNewsfoto/Stealth BioTherapeutics)
The new data demonstrated behavioral and metabolic improvements with SBT-272 in a mouse model of Huntington's disease. In the study, mice were treated for up to 8 weeks with daily SBT-272 and displayed significantly improved motor function compared to vehicle-treated mice. SBT-272-treated mice also showed improved metabolism in multiple brain regions of the diseased animals, assessed in vivo using PET imaging.
The Phase 1 clinical trial is a double-blind, placebo controlled safety study enrolling up to 64 healthy subjects across multiple cohorts. SBT-272 is being administered via subcutaneous injection. As a primary objective, the study will evaluate safety and tolerability of single and multiple ascending doses of SBT-272. Secondary objectives include an analysis of the pharmacokinetic profile of SBT-272 and identification of the appropriate dose range for Phase 2 testing.
"We see tremendous potential for SBT-272 across a spectrum of neurodegenerative diseases of mitochondrial dysfunction, with supportive preclinical data in amyotrophic lateral sclerosis, frontotemporal lobar dementia, Parkinson's and, with our new data, Huntington's disease," said Chief Executive Officer Reenie McCarthy. "It's exciting to progress this promising compound into the clinic as an important first clinical step toward initiating planned development efforts for patients affected by these devastating diseases."
About SBT-272
SBT-272 is a novel peptidomimetic which has been shown to have mitochondria-protective and neuroprotective effects across nonclinical models of amyotrophic lateral sclerosis (ALS), frontotemporal lobar dementia, alpha-synucleinopathy, a rare form of dementia that is similar to Parkinson's disease, Huntington's disease and ischemic stroke. We have also observed SBT-272-mediated improvements in functional assessments, lifespan, inflammation, and reduction of protein aggregates across certain of these nonclinical models. We are studying subcutaneous SBT-272 in a Phase 1 clinical trial in healthy human volunteers. We plan to initiate chronic toxicology studies during 2022. We hope to develop SBT-272 for ALS and other neurological diseases of mitochondrial dysfunction.
About Stealth
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. We believe our lead product candidate, elamipretide, has the potential to treat ophthalmic diseases entailing mitochondrial dysfunction, such as dry AMD, rare neuromuscular disorders, such as primary mitochondrial myopathy and Duchenne muscular dystrophy, and rare cardiomyopathies, such as Barth syndrome. We are evaluating our second-generation clinical-stage candidate, SBT-272, for rare neurological disease indications, such as amyotrophic lateral sclerosis and frontotemporal lobar dementia, following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Stealth BioTherapeutics' expectations for SBT-272 preclinical data and Phase 1 clinical development efforts, and planned SBT-272 toxicology studies. Statements that are not historical facts, including statements about Stealth BioTherapeutics' beliefs, plans and expectations, are forward-looking statements. The words "anticipate," "expect," "hope," "plan," "potential," "possible," "will," "believe," "estimate," "intend," "may," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics' ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of Stealth BioTherapeutics' product candidates and future product candidates; the preclinical and clinical results for Stealth BioTherapeutics' product candidates, which may not support further development and marketing approval; the potential advantages of Stealth BioTherapeutics' product candidates; the content and timing of decisions made by the FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Stealth BioTherapeutics product candidates; Stealth BioTherapeutics' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Stealth BioTherapeutics' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in the Stealth BioTherapeutics' most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC"), as well as in any future filings with the SEC. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-new-sbt-272-data-and-trial-initiation-301514078.html
SOURCE Stealth BioTherapeutics Inc.
$MITO news AH's...let's see if we can move north!
Grabbed some in my Roth! Looks good, and set up nice. Break into the $3.teens and the fun should start.
$AVCT $1.09 getting a push. Some volume just in the past 5-10 minutes.
$SMFL with a volume spike and jump to $1.07.
She moves in a hurry...seems to keep testing that $2.15 spike...I was prepared in case of a dip to low $2's. But back in the $2.30's now.
What kind do you want? I can run to the store quick and get you something. LOL. Or maybe just stop by one of the local micro-brew pubs in the area and grab you a growler there. ;)
$NAOV - Grabbed some at $1.17. Volume is already 1.5x the float and O/S (per Yahoo). Feel pretty good with so many shares trading in the $1.20's and above. Not sure if it will go back and try to fill the gap at all, but if it does pull back to the low $1's or sub-$1, I'll be looking to add.
$AUUD - Joined the party on this dip. Was not previously in. Agree, the volume is fantastic!
$FEMY - $2.24...I'm really liking the set up on the daily chart and what looks like a small cup and handle formation. Going to need some volume to move, especially through the 50 day...but hoping to add some in the $2 to $2.15 range if there is a dip again today.
$DRCT nice hit! Unfortunately by the time I saw the post and pulled up the L2 it was already up almost 100%.
GNUS likely getting a bump to regain compliance over the $1 minimum share price. Today was Day 5 of 10 needed to regain compliance.
A couple of potential catalysts...
In a shareholder letter issued earlier in the year, management hinted at a possibly share buyback. I don't see that that was ever formally filed for.
Last fall, they announced the acquisition of WOW. I don't believe that has ever officially closed.
I know GNUS and it has been a good trader...but the CEO is corrupt as f#@$ in my opinion. And, they (the company) don't make money. If you look at their PR's, the big ones are all related to WOW...and again, I don't believe that deal has closed.
CIDM is my long pick in the list of small streamers. Nobody is sure of them because they target enthusiasts, or as I say it..."they go after the weird shit". It's only weird to me because I don't get excited about Bob Ross, Elvis, Soccer, Horror films, etc, etc, etc. They don't have the cash GNUS has, but they have been break even or profitable for the last several quarters, and are essentially debt free. And their management team just renegotiated an acquisition that makes them the largest streamer by content...the new terms were at a 28% discount of the previously disclosed purchase price of $22M. Booming! PS - I'm long in this one.
$BEDU .63 picking up some bids.
Yeah, I think I'm going to have to start taking the pops and move onto the next. I didn't make much on THMO, but didn't have that many shares either...just never was comfortable adding.
But just looking at some of my holdings...
VIVK - Could've sold a $3+ pop last week...held, and now red.
HSTO - Could've sold the .37 pop last week...held and now just slightly green.
AVCT - Could've sold the $1.30 pop last week...held, and now slightly red.
and the list goes on...
This market is giving some big time runners...but I think the gist of it is that if you get 10% or more, you should probably just take it and move onto the next. Or at least take a good portion of it (like 80%), and then ride a small core.
$VBIV News - Up 10% PM to $1.74
They announced today that their Hep B vaccine is now available in the US. EU and Canada approval in process still. Hoping to see some good action here...I'm still a bit surprised that a big fish hasn't been trying to buy a little fish with the pps having been beat down from $3's to under $1.50 after FDA approval of this vaccine.
$CIDM News... $0.70
Company announced today that it closed the acquisition of DMR for $16M, which is renegotiated from $22M at the original announcement. This deal makes Cinedigm the streamer with the most title content of all streamers...Yep, you read that right. More content than Netflix, more than Disney, more than Paramount....yep...and all for 70 pennies.
This is one that I should've sold on last week's pop...sold my son's, but kept mine. Like THMO, it's reached the point on my "Failure To Launch" list that it's on the cutting block.
Only have 5k shares, so it's not like it's going to be a huge gainer in terms of $$$, even if it would run to .40's or .50's.
$MITQ - This one has been beaten down for a while, but it makes me wonder what drove that volume and pop? It's been perking up lately, but that jump to $1.50's was a bit unexpected. They've been extremely quiet on the PR front...was hoping maybe some news was coming.
$AVCT catching some momo.
$DGLY with a big volume spike about 10 minutes ago to take the pps to $1.18. ER date hasn't been confirmed yet by the company, but should be sometime between tomorrow and Thursday. My gut says that there is probably some short covering going on that is driving those spikes...was about 20% short a month ago, and that's down now. The shorts could never really get it to break and stay below $1, even with the shitty micro-cap market...which is a good sign that bottom is in.
For sure...I'm not chasing it now, but hope it runs a ton. It was kind of a lotto play for me...kept seeing it touch .68ish and falling back, so figured the next time it hit I'd just sell and move on.
Oh well...there will be others...
$THMO - Just my luck...LOL...I only had 1500 shares, but was getting impatient with this one so set a sell order this morning at .675. I see that triggered. LOL...go figure.
I should start posting when I'm selling stuff so everyone else knows that they should load up.
$SPCB - yeah, quite the volume spike in the past 10-20 minutes.
$SMFL - Some interesting action this morning. Watching for .93ish, as there was a gap left there on the 5 minute chart from last week...based on how $1 was holding I didn't think it would fill, but there is a battle going on here between .98 and $1.02.
It does look like Yahoo increased the float since I last checked...I was thinking it was about 6.1M last week, and now it's listed right around 8M. Still a small float, but not sure where and why the change.
$DGLY $1.14 seeing some better than usual volume early on this morning. If this can get over $1.14 here, and then get a solid break of $1.20, then we could have some fun. This one has been an extremely patient hold for me.
Me too. The only good thing is that on the daily it doesn't appear that it will leave a gap. The volume is decent for PM...just not sure if there aren't eyes on it, or if the overall markets are keeping investors away...or possibly, this news already had it's impact last week, and today we just received the official news from the company.
$MITO - Nice waking up to the news. You have a PT in mind? Seems like breaking through that .90 range might be tough.
Thanks for the heads up bro! Yes, market is shaky to say the least. The last couple of weeks have finally provided some runs, but it seems that we are far from any sort of reversal. When looking at the macro level, what kind of good news catalyst(s) do we really have?
About the only thing I can see is inflation numbers dropping in big chunks, and/or the Russia/Ukraine war ending quickly and peacefully...Everything else kind of seems like it is what it is, and will take months or years for the dust to settle.
God bless my friend! Enjoy your weekend.
$SMFL still seeing some volume after hours. Another day where it traded the float, plus some...about 1.5x the float, as listed on Yahoo at 6.1M. Waiting for some major news to drop, or another catalyst to push this northward...possibly even to the IPO price. Definitely makes you think about all of these shares trading at prices near $1.